WO2007071743A1 - Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides - Google Patents
Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides Download PDFInfo
- Publication number
- WO2007071743A1 WO2007071743A1 PCT/EP2006/070034 EP2006070034W WO2007071743A1 WO 2007071743 A1 WO2007071743 A1 WO 2007071743A1 EP 2006070034 W EP2006070034 W EP 2006070034W WO 2007071743 A1 WO2007071743 A1 WO 2007071743A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- denotes
- formula
- substituted
- alkoxycarbonyl
- Prior art date
Links
- 0 *C(c1ccc2[n](*)c(CNc(cc3)ccc3C(N3)=NOC3=O)nc2c1)=O Chemical compound *C(c1ccc2[n](*)c(CNc(cc3)ccc3C(N3)=NOC3=O)nc2c1)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- the invention relates to a process for preparing a salt of an optionally substituted 4- (benzimidazo l-2-ylmethylamino)-benzamidine, wherein (a) an optionally correspondingly substituted diaminobenzene is condensed with 2- [4-
- the main types of indication for the compound of chemical formula I are the postoperative prevention of deep vein thrombosis and the prevention of stroke (prevention of stroke due to atrial fibrillation, SPAF for short).
- the substituted (4-benzimidazol-2-ylmethylamino)- benzamidines be prepared by reacting the corresponding substituted (4-benzimidazol-2- ylmethylamino)-benzonitriles with ammonia.
- This process is highly complex from the point of view of production technology and results in a high loading of acids that have to be disposed of.
- the aim of the present invention was to indicate an alternative method of preparing the substituted (4-benzimidazol-2-ylmethylamino)-benzamidines, by which this technologically complex step could be avoided.
- a process for preparing a salt of an optionally substituted 4-(benzimidazol-2- ylmethylamino)-benzamidine of formula (I) with an inorganic or organic acid is preferred
- R 1 denotes a Ci- 6 -alkyl or C 3 _ 7 -cycloalkyl group
- R 2 denotes a Ci- 6 -alkyl group, a C 3 _ 7 -cycloalkyl group optionally substituted by a Ci- 3 -alkyl group, while the Ci- 3 -alkyl group may additionally be substituted by a carboxyl group or by a group which may be converted in vivo into a carboxy group, or (ii) denotes an R 21 NR 22 group, wherein
- R 21 denotes a C 1-6 alkyl group which may be substituted by a carboxy, C 1-6 alkoxycarbonyl, benzyloxycarbonyl, Ci- 3 -alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, trifluorosulphonylamino, trifluorosulphonylaminocarbonyl or lH-tetrazolyl group, a C 2 - 4 -alkyl group substituted by a hydroxy, phenyl-Ci-3-alkoxy, carboxy- Ci-3-alkylamino, Ci ⁇ -alkoxycarbonyl-Ci ⁇ -alkylamino, N-(Ci-3-alkyl)- carboxy-Ci-3-alkylamino or N ⁇ Ci ⁇ -alkyrj-Ci ⁇ -alkoxycarbonyl- Ci-3-alkylamino group, while in the above-mentioned groups the carbon atom in the
- R 3 denotes a hydrogen atom, a Ci- 9 -alkoxycarbonyl, cyclohexyloxycarbonyl, phenyl- Ci-3-alkoxycarbonyl, benzoyl, p-Ci-3-alkyl-benzoyl or pyridinoyl group, wherein the ethoxy moiety in the 2 position of the above-mentioned Ci- 9 -alkoxycarbonyl group may additionally be substituted by a or 2-(Ci- 3 -alkoxy)-ethyl group, while in step (a) a phenyldiamine of formula (II) wherein R 1 and R 2 have the meanings given for formula (I), is reacted with 2-[4-(l,2,4-oxadiazol-5-on-3-yl)-phenylamino]-acetic acid, the resulting product of formula (III)
- step (b)i) is hydrogenated in step (b)i), subsequently, without any prior isolation of the hydrogenation product, the compound of formula (I) thus obtained wherein R 3 denotes hydrogen is optionally reacted in step (b)ii) with a compound of formula (IV)
- R 3 -X (IV) wherein R 3 has the meaning given for formula (I), and X denotes a suitable leaving group, and then without previous isolation of the carbonylation product, in a step (b)iii) the compound of formula (I) thus obtained wherein R 1 , R 2 and R 3 are as hereinbefore defined is converted into the desired salt, particularly into a pharmaceutically acceptable salt.
- R 21 denotes a Ci -3 alkyl group which may be substituted by a carboxy, Ci -3 alkoxycarbonyl
- R 22 denotes a hydrogen atom, a Ci- 3 -alkyl group, a pyridinyl group optionally substituted by a Ci- 3 -alkyl group
- R 3 denotes a hydrogen atom, a Ci-s-alkoxycarbonyl group.
- R 22 denotes a pyridin-2-yl group
- R 3 denotes an n-hexyloxycarbonyl group.
- Preferred salts are the methanesulphonate, chloride, maleate, tartrate, salicylate, citrate and malonate of the compound of formula (I).
- a particularly preferred salt is the methanesulphonate .
- step (A) The condensation of step (a) is carried out in the presence of an inert diluent and a water-binding agent.
- the correspondingly substituted diaminobenzenes of formula (II) are known e.g. from International Patent Application WO 98/37075, e.g. from Example 25 (Steps a and b), or may be prepared analogously to those described therein.
- the solvent used may be, for example, toluene, isopropanol, triethylamine, ethanol, butyl acetate, ethyl acetate, methanol or mixtures of these solvents.
- the hydrogenation is carried out under a hydrogen pressure of 1 to 20 bar, but higher pressures are also possible.
- the concentration of the aromatic nitrogen compound (educt) is conveniently 10 to 40 wt.%; it is more preferably present in a concentration of 20 to 30 wt.%.
- the catalyst used may be for example 5-10 % palladium on charcoal, while preferably 2-20 wt.% of wet charcoal- palladium catalyst is used, based on the aromatic nitrogen compound, which corresponds to about 0.05 - 1 wt.% palladium based on the aromatic nitrogen compound.
- 3-amino-4-methylaminobenzoic acid amides are used, particularly 3-amino-4- methylaminobenzoic acid- ⁇ /-(2-pyridyl)- ⁇ /-(2-ethoxycarbonylethyl)-amide.
- the inert diluents used may be both aprotic apolar solvents - such as e.g. aliphatic or aromatic, optionally halogenated hydrocarbons - or aprotic polar solvents such as e.g. ethers and/or amides or lactams and/or mixtures thereof.
- the aprotic apolar solvents used are preferably branched or unbranched C 5 - Cs aliphatic alkanes, C4 - C 10 cycloalkanes, C 1 - C 6 aliphatic haloalkanes, C 6 - CiO aromatic alkanes or mixtures thereof.
- alkanes such as pentane, hexane or heptane, cycloalkanes such as cyclohexane or methylcyclohexane, haloalkanes such as dichloromethane, aromatic alkanes such as benzene, toluene or xylene or mixtures thereof.
- Suitable aprotic solvents are polar ethers such as, for example, tetrahydrofuran (THF), methyltetrahydrofuran, dioxane, t ⁇ t-butyl-methylether or dimethoxyethylether or amides such as, for example, dimethylformamide, or lactams such as N-methylpyrrolidone, for example.
- polar ethers such as, for example, tetrahydrofuran (THF), methyltetrahydrofuran, dioxane, t ⁇ t-butyl-methylether or dimethoxyethylether
- amides such as, for example, dimethylformamide
- lactams such as N-methylpyrrolidone, for example.
- Water-binding agents which may be used are hygroscopic salts, inorganic or organic acids or the acid chlorides thereof, anhydrides of inorganic or organic acids, anhydrides of alkanephosphonic acids, molecular sieves or urea derivatives.
- 1 , 1 '-Carbonyldiimidazoles and alkanephosphonic anhydrides are preferred, while alkanephosphonic anhydrides are particularly preferred.
- 1 '-carbonyldiimidazole is suspended in THF and heated. 2-[4-(l,2,4-Oxadiazol-5-on-3-yl)-phenylamino]-acetic acid is added.
- the correspondingly substituted diaminobenzene is added to THF.
- the reaction mixture is stirred at about 50 0 C and subsequently, after the addition of acetic acid, evaporated down and mixed with water and the solid substance is filtered off, washed and dried.
- alkanephosphonic anhydrides are added, in the presence of an organic base, preferably a tert. amine such as e.g. DIPEA, to a solution of 2-[4-(l,2,4-oxadiazol-5-on-3-yl)-phenylamino]-acetic acid and correspondingly substituted diaminobenzene in THF.
- the reaction mixture is stirred, preferably at temperatures between -10 and 50 0 C, and subsequently, after the addition of acetic acid, evaporated down. It is combined with ethanol/water and optionally a filter aid, for example kieselguhr (e.g. Clarcel ® ), and filtered hot. Then the substance precipitated from the cooled solution is filtered off, washed and dried.
- an organic base preferably a tert. amine such as e.g. DIPEA
- step (B) The hydrogenation of step (b)i) is carried out in the presence of an inert diluent and a hydrogenation catalyst.
- Particularly preferred is a process in which the hydrogenation is carried out in a temperature range from 0 0 C to 100 0 C, preferably from 0 0 C to 70 0 C, particularly from 25°C to 60 0 C.
- the inert diluents may be both protic solvents - such as e.g. alcohols, carboxylic acids and/or water, or aprotic polar solvents such as e.g. ethers and/or amides or lactams and/or mixtures thereof. Water may optionally be added to all the solvents.
- the protic solvents used are preferably branched or unbranched Ci - Cs alkanols, Ci - C 3 carboxylic acids or mixtures thereof. Particularly preferably, lower alcohols such as methanol, ethanol, n-propanol and isopropanol, carboxylic acids such as formic acid, acetic acid and propionic acid or mixtures thereof are used.
- Suitable aprotic solvents include polar ethers such as for example tetrahydrofuran, dioxane or dimethoxyethylether or amides such as for example dimethylformamide, or lactams such as for example N-methylpyrrolidone. Particularly preferred are THF and/or acetic acid, which may optionally contain water in any proportion.
- solvents with a low tendency to flammability are used.
- Aprotic solvents are preferable to pro tic solvents during the hydrogenation.
- Suitable hydrogenation catalysts are generally transition metals such as for example nickel, platinum or palladium or the salts or oxides thereof. Raney nickel, platinum oxide and palladium on an inert carrier material, particularly palladium on activated charcoal (Pd/C) are preferred.
- step (a) Processes in which the product of step (a) is used in a ratio by weight to the hydrogenation catalyst of 1:1 to 1000:1, preferably from 5:1 to 100:1 during hydrogenation are preferred.
- step (b)i) the product of step (a) is taken up in THF/water (7:3 based on the volume) and hydrogenated at 4 bar hydrogen with water-moistened 10% Pd/C at about 40 0 C.
- the catalyst is filtered off, the filter is washed with THF/water (7:3) and the filtrate is clarified with active charcoal.
- the charcoal is filtered off and the filter is washed with THF and water. The filtrate thus obtained is reacted further directly in step b)ii).
- step (C) The optional subsequent carbonylation in step (b)ii), in order to obtain from a compound of formula (I), wherein R 3 denotes hydrogen, a compound of formula (I) wherein R 3 has a meaning other than hydrogen, without intermediate isolation of the hydrogenation product, is carried out by direct reaction of the compound of formula (I) obtained in step (b)i), wherein R 3 denotes hydrogen, with a carbonylation agent R 3 -X, where R 3 has the meanings given above with the exception of hydrogen and X denotes a leaving group.
- X may denote a halogen such as for example chlorine or bromine or a p-toluenesulphonyl, methanesulphonyl or trifluoromethanesulphonyl group.
- a halogen such as for example chlorine or bromine or a p-toluenesulphonyl, methanesulphonyl or trifluoromethanesulphonyl group.
- R 3 denotes n-hexyl.
- the reaction is preferably carried out at a temperature of 0 to 50 0 C, in particular at 10 to 20 0 C in the presence of a base.
- the base used may conveniently be an alkali metal carbonate such as for example potassium carbonate or sodium carbonate, an alkali metal hydrogen carbonate such as for example sodium hydrogen carbonate or potassium hydrogen carbonate or a tertiary amine such as for example triethylamine.
- an alkali metal carbonate such as for example potassium carbonate or sodium carbonate
- an alkali metal hydrogen carbonate such as for example sodium hydrogen carbonate or potassium hydrogen carbonate or a tertiary amine such as for example triethylamine.
- potassium carbonate is used.
- the reaction may for example be carried out in mixtures of water and acetone, water and dioxane or water and THF; a water/THF mixture is preferred.
- a clear two-phase mixture may be formed by heating the suspension, e.g. to approx. 50 0 C, so that the aqueous phase, which contains a large proportion of the inorganic constituents, can be separated off. Then a change of solvent may take place.
- suitable solvents include for example ketones or esters such as MIBK, butyl acetate, ethyl acetate, propyl acetate, isopropyl acetate or isobutyl acetate.
- MIBK or butyl acetate are used; butyl acetate is particularly preferred.
- the carbonylation agent for example n-hexyl chloro formate
- the suspension is heated to 50 0 C during which time a clear two-phase mixture is formed.
- further carbonylation agent is optionally metered in at approx. 50 0 C until the reaction of the educt is complete.
- the THF is distilled off and replaced by butyl acetate.
- the organic phase is repeatedly washed with water with heating to 50 - 70 0 C, in order to eliminate polar impurities. Any residual moisture remaining is subsequently removed by azeotropic distillation.
- a change of solvent may take place before the precipitation of the salt in step (b)iii) a change of solvent may take place.
- the organic solvent used previously such as butyl acetate
- Suitable solvents for the partial step (b)iii) include for example ketones such as for example acetone or MIBK, ethers such as for example THF, esters such as for example ethyl acetate, isopropyl acetate or butyl acetate or alcohols such as for example methanol, ethanol or isopropanol.
- acetone and/or ethanol are used, particularly preferably a mixture of the two solvents is used.
- the desired salt may be precipitated and isolated directly.
- the suspension is stirred, and the precipitated product is isolated by filtration, washed with acetone and dried under suitable conditions.
- the inert diluents used may be both protic solvents - such as e.g. alcohols, and/or water - or aprotic polar solvents such as e.g. ethers and/or amides or lactams and/or mixtures thereof. Water may optionally be added to all the solvents.
- Protic solvents used are preferably water or branched or unbranched Ci - Cs alkanols or mixtures thereof. Particularly preferably, water or lower alcohols such as methanol, ethanol, n-propanol and isopropanol or mixtures thereof are used. Most particularly preferably, ethanol is used as reaction medium, and this may optionally contain water.
- Isopropanol optionally together with water, may also be used.
- the most suitable solvent is water, however.
- Suitable aprotic solvents are polar ethers such as for example tetrahydrofuran or dimethoxy- ethylether or amides such as for example dimethylformamide, or lactams such as for example N-methylpyrrolidone.
- ethyl bromoacetate is metered into a suspension of 2-[4-(l,2,4-oxadiazol-5-on-3-yl)-aniline and sodium carbonate in water/isopropanol or preferably in water/ethanol and stirred at 35-45°C.
- the cooled suspension is suction filtered, washed with water and ethanol in several batches and dried.
- the saponification is preferably carried out in a pro tic solvent with an alkali metal or alkaline earth metal hydroxide, particularly with lithium, sodium or potassium hydroxide.
- 2-[4-(l,2,4-oxadiazol-5-on-3-yl)-phenylamino]- acetic acid ester is suspended in water or preferably in water/ethanol and slowly combined with an aqueous solution of NaOH at ambient temperature.
- the suspension changes into a solution and is heated to 45 to 75°C.
- HCl is added to the solution thus obtained until a pH of about 5 or preferably pH 3 is achieved.
- the solid is isolated and washed with cold water and cold ethanol and MtBE.
- 4-aminophenyl-amidoxime may be prepared e.g. by reacting 4-aminobenzonitrile with hydroxylamine hydrochloride.
- sodium methoxide or preferably sodium ethoxide is added at 65-75°C, preferably at 70 - 75°C, to a suspension of 4-aminophenyl-amidoxime in ethanol and rinsed with ethanol. After 15 min stirring diethyl carbonate or preferably dimethyl carbonate is added dropwise. After 2-4 hours reaction time the mixture is cooled and ethanol is distilled off at 120 mbar and 40 0 C. The residue is taken up in water and after heating adjusted to pH 10-12 using semi-cone, sodium hydroxide solution, then to pH ⁇ 6, preferably to pH ⁇ 4, particularly preferably to pH 2-3, by acidifying with cone, hydrochloric acid, and slowly cooled. The solution changes into a suspension, which is filtered and washed several times with cold water and ethanol.
- the working up of the individual reactions may take place in the conventional manner, for example, by separating off the reaction adjuvants, eliminating the solvent and isolating pure end product from the residue by crystallisation, distillation, extraction or chromatography.
- the physiologically acceptable salts may be salts with inorganic or organic acids or, if the compound contains a carboxy group, with inorganic or organic bases.
- acids for this purpose include methanesulphonic acid, hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
- bases which may be used include sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
- the compound of formula (6 ⁇ is preferably converted into its mesylate.
- the suspension cooled to 0 0 C is suction filtered, washed in several batches with 100 ml of ethanol and dried at max. 50 0 C in vacuo.
- the ester (2A) (86.9 g; 0.33 mol) thus obtained is suspended in 400 ml of water or preferably ethanol/water (1 : 1) and at RT 120 g of 45% NaOH are slowly added dropwise. The suspension goes into solution and is reddish (pH 12.5). It is heated to ⁇ 60°C and saponified for 1 h. The solution obtained is combined batchwise with HCl (37% or preferably with cone. HCl), until a pH 3 is obtained. It is cooled to 0 0 C. The solid is suction filtered and washed in several batches with a total of 400 ml cold water as well as 40 ml cold ethanol. 81.4 g moist substance are obtained. It is dried at 35°C in vacuo. Yield: 76.7 g substance (98% of theory) melting point: from 193°C (decomp.) purity: > 99% HPLC peak area
- Variant A Pd/C 5%
- Variant A CDI as coupling reagent
- reaction mixture is stirred for approx. 18 h and subsequently, after the addition of 100 ml acetic acid, refluxed, so that the THF is distilled off. After approx. 1 h the mixture is combined with 400 ml of water and stirred.
- Variant B PPA as coupling reagent 34.2 g (0.1 mol) AMBPA 3, 27.5 g (0.12 mol) (2B) and 30.3 g (0.23 mol) DIPEA are placed in 170 ml THF and cooled to somewhat below ambient temperature. Now 85 g (0.13 mol) PPA (as -50% solution in ethyl acetate) are metered in. The mixture is stirred for another 90 min and then the solvent is distilled off. Towards the end 73.5 g acetic acid are added and the mixture is heated to an internal temperature of 90 0 C. Then 400 ml of ethanol or preferably 400 ml of ethano I/water (approx.
- the hydrogenation solution is filtered and the filter is washed with 75 g THF/water (7:3).
- the filtrate is combined successively with 56 ml THF, 260 ml of water and batchwise with 75.2 g (544 mmol) potassium carbonate at ambient temperature.
- 14.2 g (86 mmol) of n-hexylchloroformate are metered in over 40 min.
- a further 1.2 g (7.3 mmol) n-hexylchloroformate are metered in, so that all the starting material is reacted.
- the suspension is heated to approx. 45°C. A clear two-phase mixture is formed.
- the aqueous phase is discarded and the THF is largely distilled off.
- Example 7 Preparation of l-methyl-2-[ ⁇ L [4-( ⁇ L n-hexyloxycarbonylamidino)phenyl]-amino- methyl]-benzimidazol-5-yl-carboxylic acid- ⁇ L (2-pyridyl)- ⁇ L (2-ethoxycarbonylethyl)- amide mesylate (7) from l-methyl-2-[ ⁇ L [4-(l,2,4-oxadiazol-5-on-3-yl)phenyl]-amino- methyl]-benzimidazol-5-yl-carboxylic acid- ⁇ L (2-pyridyl)- ⁇ L (2-ethoxycarbonylethyl)- amide (4) 60 g (91 mmol) of 4 (optionally containing acetate) are hydrogenated with 3.0 g 10% palladium on charcoal (moistened with water) in 126 ml THF and 54 ml of water at 40 0 C and 4 bar
- the hydrogenation solution is filtered, the filter is washed with 51 g THF/water (7:3) and the filtrate is carburised.
- the activated charcoal is filtered off and the filter is washed with 102 ml THF and 80 ml of water.
- the filtrate is combined at ambient temperature with a solution of 75.2 g (544 mmol) potassium carbonate in 80 ml of water and at 10-20 0 C 14.6 g (88.9 mmol) n-hexylchloro formate are metered in over 1 h.
- the suspension is heated to approx. 50 0 C.
- a clear two-phase mixture is formed, into which a further 0.452 g (2.7 mmol) n-hexylchloroformate are metered in after the conversion has been checked, so that all the starting material is reacted.
- 180 ml THF are subsequently distilled off and replaced by 350 ml butyl acetate.
- the organic phase is extracted twice with 30 ml of water at 50-70 0 C, 210 ml butyl acetate are distilled off and replaced by 300 ml acetone and 60 ml of ethanol.
- the reaction solution is cooled to 30-36 0 C, mixed with seed crystals of 7 (which have been obtained for example from a previous reaction according to Example 5 or using the process described in Example 3 of WO 03/074056) and a previously prepared solution of 7.84 g (82 mmol) methanesulphonic acid in 50 ml acetone is added dropwise.
- the suspension is stirred, the product is isolated by filtration and washed with acetone.
- the isolated substance is dried at 45 0 C in vacuo. Yield: 56.2 g (86 %) purity: > 99% HPLC peak area
- the other compounds of formula (I) and the salts thereof may be prepared analogously to the foregoing Examples.
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK06830756.0T DK1968949T3 (en) | 2005-12-21 | 2006-12-20 | Improved Process for the Preparation of Salts of 4- (Benzimidazolylmethylamino) Benzamides |
PL06830756T PL1968949T3 (en) | 2005-12-21 | 2006-12-20 | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides |
KR1020087017836A KR101411961B1 (en) | 2005-12-21 | 2006-12-20 | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides |
EP06830756A EP1968949B1 (en) | 2005-12-21 | 2006-12-20 | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides |
NZ569636A NZ569636A (en) | 2005-12-21 | 2006-12-20 | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides |
JP2008546456A JP5317702B2 (en) | 2005-12-21 | 2006-12-20 | Improved process for the preparation of salts of 4- (benzimidazolylmethylamino) -benzamide |
CA2632310A CA2632310C (en) | 2005-12-21 | 2006-12-20 | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides |
SI200630879T SI1968949T1 (en) | 2005-12-21 | 2006-12-20 | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides |
BRPI0620150-4A BRPI0620150A2 (en) | 2005-12-21 | 2006-12-20 | improved process of preparing 4- (benzimidazolyl methylamine) -benzamides salts |
DE602006017743T DE602006017743D1 (en) | 2005-12-21 | 2006-12-20 | IMPROVED METHOD FOR PREPARING THE SALTS OF 4- (BENZIMIDAZOLYLMETHYLAMINE) -BENZAMIDES |
AU2006326980A AU2006326980B2 (en) | 2005-12-21 | 2006-12-20 | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides |
AT06830756T ATE485279T1 (en) | 2005-12-21 | 2006-12-20 | IMPROVED METHOD FOR PREPARING THE SALTS OF 4-(BENZIMIDAZOLYLMETHYLAMIN)-BENZAMIDES |
CN2006800488945A CN101346355B (en) | 2005-12-21 | 2006-12-20 | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides |
IL192242A IL192242A (en) | 2005-12-21 | 2008-06-17 | Process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005061624.0 | 2005-12-21 | ||
DE102005061624A DE102005061624A1 (en) | 2005-12-21 | 2005-12-21 | Improved process for the preparation of salts of 4- (benzimidazolylmethylamino) -benzamidines |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007071743A1 true WO2007071743A1 (en) | 2007-06-28 |
Family
ID=37950582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/070034 WO2007071743A1 (en) | 2005-12-21 | 2006-12-20 | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides |
Country Status (23)
Country | Link |
---|---|
US (1) | US7880016B2 (en) |
EP (1) | EP1968949B1 (en) |
JP (1) | JP5317702B2 (en) |
KR (1) | KR101411961B1 (en) |
CN (1) | CN101346355B (en) |
AR (1) | AR058571A1 (en) |
AT (1) | ATE485279T1 (en) |
AU (1) | AU2006326980B2 (en) |
BR (1) | BRPI0620150A2 (en) |
CA (1) | CA2632310C (en) |
CY (1) | CY1111113T1 (en) |
DE (2) | DE102005061624A1 (en) |
DK (1) | DK1968949T3 (en) |
ES (1) | ES2355045T3 (en) |
IL (1) | IL192242A (en) |
NZ (1) | NZ569636A (en) |
PL (1) | PL1968949T3 (en) |
PT (1) | PT1968949E (en) |
RU (1) | RU2425827C2 (en) |
SI (1) | SI1968949T1 (en) |
TW (1) | TWI411608B (en) |
WO (1) | WO2007071743A1 (en) |
ZA (1) | ZA200804198B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008059029A2 (en) * | 2006-11-16 | 2008-05-22 | Boehringer Ingelheim International Gmbh | New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate |
WO2009153214A1 (en) * | 2008-06-16 | 2009-12-23 | Boehringer Ingelheim International Gmbh | Process for the manufacture of an intermediate in the synthesis of dabigatran |
WO2011061080A1 (en) | 2009-11-18 | 2011-05-26 | Boehringer Ingelheim International Gmbh | Method for producing dabigatran etexilate |
JP2011524403A (en) * | 2008-06-16 | 2011-09-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Method for producing an intermediate product of dabigatran etexilate |
EP2649060A2 (en) * | 2010-12-06 | 2013-10-16 | MSN Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
WO2014033693A1 (en) * | 2012-08-31 | 2014-03-06 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form i of methanesulfonate salt of dabigatran etexilate |
WO2014064016A1 (en) | 2012-10-22 | 2014-05-01 | Boehringer Ingelheim International Gmbh | Process for the manufacture of 4-aminobenzoamidine dihydrochloride |
WO2014068587A2 (en) * | 2012-10-29 | 2014-05-08 | Biophore India Pharmaceuticals Pvt. Ltd. | An improved process for the synthesis of dabigatran and its intermediates |
US9086390B2 (en) | 2011-05-11 | 2015-07-21 | Medichem, S.A. | Dabigatran etexilate and related substances, processes and compositions, and use of the substances as reference standards and markers |
US10077251B2 (en) | 2012-10-29 | 2018-09-18 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the synthesis of Dabigatran Etexilate and its intermediates |
US10112901B2 (en) | 2014-07-03 | 2018-10-30 | Shanghai Institute Of Pharmaceutical Industry | Method for preparing dabigatran etexilate intermediate, and intermediate compound |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
DE10339862A1 (en) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis |
DE102005061623A1 (en) * | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Improved process for the preparation of 4- (benzimidazolylmethylamino) -benzamidines and their salts |
US8173906B2 (en) * | 2007-02-07 | 2012-05-08 | Raytheon Company | Environmental protection coating system and method |
US7767589B2 (en) * | 2007-02-07 | 2010-08-03 | Raytheon Company | Passivation layer for a circuit device and method of manufacture |
RU2010143901A (en) * | 2008-03-28 | 2012-05-10 | Бёрингер Ингельхайм Интернациональ Гмбх (De) | METHOD FOR OBTAINING DABIGATRAN COMPOSITIONS FOR ORAL ADMINISTRATION |
AR072557A1 (en) * | 2008-07-14 | 2010-09-08 | Boehringer Ingelheim Int | PROCESS TO PREPARE COMPOSITIONS OF DRUGS CONTAINING DABIGATRAN |
NZ592616A (en) | 2008-11-11 | 2013-04-26 | Boehringer Ingelheim Int | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy |
EP2545044A1 (en) * | 2010-03-08 | 2013-01-16 | ratiopharm GmbH | Dabigatran etexilate-containing pharmaceutical composition |
WO2013150545A2 (en) * | 2012-04-02 | 2013-10-10 | Msn Laboratories Limited | Process for the preparation of benzimidazole derivatives and salts thereof |
CN103275065A (en) * | 2013-05-30 | 2013-09-04 | 上海同昌生物医药科技有限公司 | Novel method for producing dabigatran etexilate |
EP2835370A1 (en) | 2013-08-08 | 2015-02-11 | Medichem, S.A. | New crystals of dabigatran etexilate mesylate |
CN105461686A (en) * | 2014-08-25 | 2016-04-06 | 江苏豪森药业股份有限公司 | Preparation method of high purity Pradaxa crystal form |
CN104987323B (en) * | 2015-07-10 | 2017-08-22 | 浙江美诺华药物化学有限公司 | A kind of preparation method of dabigatran etcxilate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037075A1 (en) * | 1997-02-18 | 1998-08-27 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, their production and use as medicaments |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087380A (en) * | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
TWI248435B (en) * | 1998-07-04 | 2006-02-01 | Boehringer Ingelheim Pharma | Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions |
US6248770B1 (en) * | 1998-07-09 | 2001-06-19 | Boehringer Ingelheim Pharma Kg | Benzimidazoles having antithrombotic activity |
US6451832B2 (en) * | 1999-12-23 | 2002-09-17 | Boehringer Ingelheim Pharma Kg | Benzimidazoles with antithrombotic activity |
DE19962329A1 (en) | 1999-12-23 | 2001-06-28 | Boehringer Ingelheim Pharma | New substituted 2-(phenylaminomethyl)-benzimidazoles, used as thrombin inhibitors, serine protease inhibitors, antithrombotic agents and intermediates |
PT1870100E (en) * | 2002-03-07 | 2012-04-17 | Boehringer Ingelheim Int | Ethyl 3-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1h-benzimidazole-5-carbonyl)-2-pyridylamino)propionate methansulfonate |
NL1026498C2 (en) * | 2004-06-24 | 2005-12-28 | Free Lift B V | Slope lift unit with blocking device and blocking device intended for slope lift unit. |
EP1609784A1 (en) * | 2004-06-25 | 2005-12-28 | Boehringer Ingelheim Pharma GmbH & Co.KG | Process for the preparation of 4-(benzimidazolylmethylamino)-benzamidines |
DE102005061623A1 (en) * | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Improved process for the preparation of 4- (benzimidazolylmethylamino) -benzamidines and their salts |
-
2005
- 2005-12-21 DE DE102005061624A patent/DE102005061624A1/en not_active Withdrawn
-
2006
- 2006-12-20 JP JP2008546456A patent/JP5317702B2/en active Active
- 2006-12-20 KR KR1020087017836A patent/KR101411961B1/en active IP Right Grant
- 2006-12-20 AT AT06830756T patent/ATE485279T1/en active
- 2006-12-20 AR ARP060105633A patent/AR058571A1/en not_active Application Discontinuation
- 2006-12-20 DK DK06830756.0T patent/DK1968949T3/en active
- 2006-12-20 WO PCT/EP2006/070034 patent/WO2007071743A1/en active Application Filing
- 2006-12-20 SI SI200630879T patent/SI1968949T1/en unknown
- 2006-12-20 PL PL06830756T patent/PL1968949T3/en unknown
- 2006-12-20 DE DE602006017743T patent/DE602006017743D1/en active Active
- 2006-12-20 TW TW095148016A patent/TWI411608B/en not_active IP Right Cessation
- 2006-12-20 BR BRPI0620150-4A patent/BRPI0620150A2/en not_active Application Discontinuation
- 2006-12-20 AU AU2006326980A patent/AU2006326980B2/en active Active
- 2006-12-20 ES ES06830756T patent/ES2355045T3/en active Active
- 2006-12-20 PT PT06830756T patent/PT1968949E/en unknown
- 2006-12-20 NZ NZ569636A patent/NZ569636A/en unknown
- 2006-12-20 EP EP06830756A patent/EP1968949B1/en active Active
- 2006-12-20 CN CN2006800488945A patent/CN101346355B/en active Active
- 2006-12-20 RU RU2008129637/04A patent/RU2425827C2/en active
- 2006-12-20 CA CA2632310A patent/CA2632310C/en active Active
- 2006-12-21 US US11/614,299 patent/US7880016B2/en active Active
-
2008
- 2008-05-15 ZA ZA200804198A patent/ZA200804198B/en unknown
- 2008-06-17 IL IL192242A patent/IL192242A/en active IP Right Grant
-
2011
- 2011-01-14 CY CY20111100047T patent/CY1111113T1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037075A1 (en) * | 1997-02-18 | 1998-08-27 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, their production and use as medicaments |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008059029A3 (en) * | 2006-11-16 | 2008-08-07 | Boehringer Ingelheim Int | New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate |
WO2008059029A2 (en) * | 2006-11-16 | 2008-05-22 | Boehringer Ingelheim International Gmbh | New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate |
US8471033B2 (en) | 2008-06-16 | 2013-06-25 | Boehringer Ingelheim International Gmbh | Method for producing an intermediate product of dabigatran etexilate |
WO2009153214A1 (en) * | 2008-06-16 | 2009-12-23 | Boehringer Ingelheim International Gmbh | Process for the manufacture of an intermediate in the synthesis of dabigatran |
JP2011524403A (en) * | 2008-06-16 | 2011-09-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Method for producing an intermediate product of dabigatran etexilate |
JP2011524402A (en) * | 2008-06-16 | 2011-09-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Method for producing an intermediate for the synthesis of dabigatran |
US8378113B2 (en) | 2008-06-16 | 2013-02-19 | Boehringer Ingelheim International Gmbh | Process for the manufacture of an intermediate in the synthesis of dabigatran |
US8993770B2 (en) | 2009-11-18 | 2015-03-31 | Boehringer Ingelheim International Gbmh | Process for the manufacture of dabigatran etexilate |
WO2011061080A1 (en) | 2009-11-18 | 2011-05-26 | Boehringer Ingelheim International Gmbh | Method for producing dabigatran etexilate |
US8399678B2 (en) | 2009-11-18 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dabigatran etexilate |
EP2649060A2 (en) * | 2010-12-06 | 2013-10-16 | MSN Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
EP2649060A4 (en) * | 2010-12-06 | 2014-07-09 | Msn Lab Ltd | Process for the preparation of benzimidazole derivatives and its salts |
US9086390B2 (en) | 2011-05-11 | 2015-07-21 | Medichem, S.A. | Dabigatran etexilate and related substances, processes and compositions, and use of the substances as reference standards and markers |
WO2014033693A1 (en) * | 2012-08-31 | 2014-03-06 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form i of methanesulfonate salt of dabigatran etexilate |
US9150542B2 (en) | 2012-08-31 | 2015-10-06 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form I of methanesulfonate salt of dabigatran etexilate |
WO2014064016A1 (en) | 2012-10-22 | 2014-05-01 | Boehringer Ingelheim International Gmbh | Process for the manufacture of 4-aminobenzoamidine dihydrochloride |
WO2014068587A3 (en) * | 2012-10-29 | 2014-07-17 | Biophore India Pharmaceuticals Pvt. Ltd. | An improved process for the synthesis of dabigatran and its intermediates |
WO2014068587A2 (en) * | 2012-10-29 | 2014-05-08 | Biophore India Pharmaceuticals Pvt. Ltd. | An improved process for the synthesis of dabigatran and its intermediates |
US9533971B2 (en) | 2012-10-29 | 2017-01-03 | Biophore India Pharmaceuticals Pvt. Ltd | Process for the synthesis of dabigatran and its intermediates |
US10077251B2 (en) | 2012-10-29 | 2018-09-18 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the synthesis of Dabigatran Etexilate and its intermediates |
US10112901B2 (en) | 2014-07-03 | 2018-10-30 | Shanghai Institute Of Pharmaceutical Industry | Method for preparing dabigatran etexilate intermediate, and intermediate compound |
Also Published As
Publication number | Publication date |
---|---|
EP1968949A1 (en) | 2008-09-17 |
AR058571A1 (en) | 2008-02-13 |
US7880016B2 (en) | 2011-02-01 |
IL192242A0 (en) | 2008-12-29 |
RU2425827C2 (en) | 2011-08-10 |
PL1968949T3 (en) | 2011-04-29 |
TWI411608B (en) | 2013-10-11 |
CN101346355B (en) | 2012-09-05 |
DK1968949T3 (en) | 2011-01-24 |
ZA200804198B (en) | 2009-04-29 |
ES2355045T3 (en) | 2011-03-22 |
KR20080081179A (en) | 2008-09-08 |
AU2006326980A1 (en) | 2007-06-28 |
EP1968949B1 (en) | 2010-10-20 |
CA2632310C (en) | 2014-02-11 |
CY1111113T1 (en) | 2015-06-11 |
US20070185173A1 (en) | 2007-08-09 |
CA2632310A1 (en) | 2007-06-28 |
BRPI0620150A2 (en) | 2011-11-01 |
DE602006017743D1 (en) | 2010-12-02 |
IL192242A (en) | 2012-02-29 |
NZ569636A (en) | 2010-04-30 |
ATE485279T1 (en) | 2010-11-15 |
SI1968949T1 (en) | 2011-02-28 |
JP2009520766A (en) | 2009-05-28 |
DE102005061624A1 (en) | 2007-06-28 |
TW200740791A (en) | 2007-11-01 |
PT1968949E (en) | 2010-12-22 |
RU2008129637A (en) | 2010-01-27 |
JP5317702B2 (en) | 2013-10-16 |
KR101411961B1 (en) | 2014-06-27 |
AU2006326980B2 (en) | 2012-07-05 |
CN101346355A (en) | 2009-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1968949B1 (en) | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides | |
US8354543B2 (en) | Process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof | |
CA2570499C (en) | Method for producing 4-(benzimidazolylmethylamino)-benzamidines | |
MX2008007170A (en) | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides | |
MX2008007051A (en) | Improved process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680048894.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006830756 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2632310 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/007170 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5045/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501512 Country of ref document: PH Ref document number: 2008546456 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 569636 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006326980 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008129637 Country of ref document: RU Ref document number: 1020087017836 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006326980 Country of ref document: AU Date of ref document: 20061220 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006326980 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006830756 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0620150 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080620 |